Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02267629 · ClinicalTrials.gov registry record · Phase 2

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

A Phase 2 study of Obsessive Compulsive Disorder (OCD), sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target
1
Study location

NCT02267629: Completed Phase 2 study of Obsessive Compulsive Disorder (OCD), sponsored by New York State Psychiatric Institute.

NCT02267629 is a Phase 2 study of Obsessive Compulsive Disorder (OCD) that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 7 participants, below the 243-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02267629, a Phase 2 study of Obsessive Compulsive Disorder (OCD), has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.

Primary Outcome

Patients self-rated the severity of their obsessions and compulsions using the YBOC Challenge Scale, a 10-item self-report form that assesses Obsessive Compulsive Disorder (OCD) symptoms (i.e., time spent, degree of control, severity) \[total score range = 0 - 40 \] over the previous 60 minutes. The higher the number on the YBOCCS, the more severe the symptoms.

Conditions Studied

Obsessive Compulsive Disorder (OCD)

Interventions

  • DRUG Rapastinel (formerly GLYX-13)

Study Locations (1)

New York

  • New York State Psychiatric Insitute - New York

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2014-10
Est. Completion 2016-02
Phase Phase 2
New York State Psychiatric Institute

364 total trials

What the finished NCT02267629 record still lists

NCT02267629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 243-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Obsessive Compulsive Disorder (OCD) appearing as the primary indexed condition, and to 1 intervention - of which Rapastinel (formerly GLYX-13) is the first listed.

NCT02267629 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02267629 about?

NCT02267629 is a clinical study titled "Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder". This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respon...

What is the current status of trial NCT02267629?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-10. Estimated completion is 2016-02.

What conditions does trial NCT02267629 study?

This clinical trial studies the following conditions: Obsessive Compulsive Disorder (OCD).

What interventions are being tested in trial NCT02267629?

The interventions under investigation include: Rapastinel (formerly GLYX-13) (DRUG).

Who is sponsoring clinical trial NCT02267629?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02267629 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obsessive Compulsive Disorder (OCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02267629's enrollment target sits among peer trials

7 13th of 12 the lowest of 12 other Obsessive Compulsive Disorder (OCD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive Compulsive Disorder (OCD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02267629, the US trial registry maintained by the National Library of Medicine. NCT02267629 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.